{%lSlanguageSelectorLabel%}
{%lSactiveLanguage%}This website is for UK Healthcare Professionals only
This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.
UK-VNCAML-240003 | April 2024.
UK-VNCAML-240075 | April 2024.
VENCLYXTO in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1
You are advised to read the Prescribing Information and Summary of Product Characteristics (GB SmPC; NI SmPC) to evaluate patient suitability for VENCLYXTO.
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
To direct you to the most appropriate information, please confirm:
I am a UK Healthcare Professional.
This AbbVie website is intended for UK Healthcare Professionals only and contains promotional content.
I am a member of the public based in the UK
Report adverse events (healthcare professionals in the UK)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie at GBPV@abbvie.com
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at GBPV@abbvie.com
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle:
▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at GBPV@abbvie.com
UK-ABBV-230223. Date of preparation: June 2023
